Company Update (NASDAQ:CERS): Cerus Corporation and Bonfils Blood Center Enter Into Agreement for the Use of INTERCEPT Platelets and Plasma

Cerus Corporation (NASDAQ:CERS) announced that Bonfils Blood Center has signed a three-year purchase agreement for the INTERCEPT Blood System for platelets and plasma. Bonfils provides blood and blood products to more than 100 hospitals and healthcare facilities across Colorado and beyond, supplying approximately 20,000 platelet and 25,000 plasma units per year. Bonfils is an affiliate of Blood Systems Inc., one of the largest blood product and service providers in the U.S.

“We are excited to partner with Cerus to make INTERCEPT pathogen reduction another important option for our healthcare clients as we work in collaboration to deliver on our mission to ‘save and enhance lives through transfusion medicine excellence,’” said Bryan Krueger, Bonfils Blood Center President and Chief Executive Officer.

“We are pleased to offer the use of INTERCEPT pathogen reduction to enhance the quality of care provided at the hospitals we serve and for the patients for which they provide treatment,” said Tuan Le, MD, Medical Director and Vice President of Medical Affairs atBonfils Blood Center.

“Bonfils has been a valuable research partner for us, contributing significantly to studies we’ve used to support our current FDA approvals and also future product extensions,” commented William “Obi” Greenman, Cerus’ President and Chief Executive Officer. “We are pleased to expand this relationship and now become their pathogen reduction supplier.” (Original Source)

Shares of Cerus closed last Friday at $5.06. CERS has a 1-year high of $7.03 and a 1-year low of $3.48. The stock’s 50-day moving average is $5.21 and its 200-day moving average is $4.97.

On the ratings front, Cerus has been the subject of a number of recent research reports. In a report issued on June 29, MLV & Co. analyst Thomas Yip reiterated a Buy rating on CERS, with a price target of $10, which represents a potential upside of 97.6% from where the stock is currently trading. Separately, on May 27, Cantor Fitzgerald’s Caroline Corner reiterated a Buy rating on the stock and has a price target of $7.

According to, which ranks over 7,500 financial analysts and bloggers to gauge the performance of their past recommendations, Thomas Yip and Caroline Corner have a total average return of 2.7% and -14.0% respectively. Yip has a success rate of 50.0% and is ranked #1957 out of 3694 analysts, while Corner has a success rate of 30.0% and is ranked #3565.

Cerus Corp is a biomedical products company. It is engaged indeveloping andcommercializing the INTERCEPT Blood System to enhance blood safety.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts